DelveInsight’s, “Chronic Hepatitis B Virus Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Chronic Hepatitis B Virus pipeline landscape. It covers the Chronic Hepatitis B Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Chronic Hepatitis B Virus Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Hepatitis B Virus Pipeline Outlook
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
- In July 2025, Gilead Sciences announced a clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
- In July 2025, Seng Gee Lim conducted a study to determine the possibility of HBsAg loss in Chronic Hepatitis B carriers in a randomised open label clinical trial comparing no treatment to 24 weeks peg-interferon alpha 2a or 48 weeks peginterferon alpha 2a (randomised 1:1:1). The primary endpoint of HBsAg loss will be evaluated 24 weeks after the end of therapy for those on therapy and matched to an equivalent timepoint in the control arm. The sample size calculation is 30 patients in each arm for a 20% difference between any experimental arm and the control arm.
- In July 2025, Fujian Shengdi Pharmaceutical Co., Ltd. organized a Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
- DelveInsight’s Chronic Hepatitis B Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Chronic Hepatitis B Virus treatment.
- The leading Chronic Hepatitis B Virus Companies such as Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm. And others.
- Promising Chronic Hepatitis B Virus Pipeline Therapies such as Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.
Stay ahead with the most recent pipeline outlook for Chronic Hepatitis B Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Hepatitis B Virus Treatment Drugs
Chronic Hepatitis B Virus Emerging Drugs Profile
- Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand’s HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.
- RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.
The Chronic Hepatitis B Virus Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
- Chronic Hepatitis B Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market
Explore groundbreaking therapies and clinical trials in the Chronic Hepatitis B Virus Pipeline. Access DelveInsight's detailed report now! @ New Chronic Hepatitis B Virus Drugs
Chronic Hepatitis B Virus Companies
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm and others.
Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Chronic Hepatitis B Virus Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Unveil the future of Chronic Hepatitis B Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Hepatitis B Virus Market Drivers and Barriers
Scope of the Chronic Hepatitis B Virus Pipeline Report
- Coverage- Global
- Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm. And others.
- Chronic Hepatitis B Virus Pipeline Therapies- Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.
- Chronic Hepatitis B Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chronic Hepatitis B Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chronic Hepatitis B Virus Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Hepatitis B Virus Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Chronic Hepatitis B Virus Infection: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Hepatitis B Virus Infection – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Pradefovir: Ligand Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RG6346: Dicerna Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- VIR-3434: Vir Biotechnology
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- SBT8230: Silverback Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Hepatitis B Virus Infection Key Companies
- Chronic Hepatitis B Virus Infection Key Products
- Chronic Hepatitis B Virus Infection - Unmet Needs
- Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
- Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
- Chronic Hepatitis B Virus Infection Analyst Views
- Chronic Hepatitis B Virus Infection Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight
